NRIX
Nurix Therapeutics Inc
22.20$
-2.3%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 113.0% | 114.0% | 104.0% | 688.7% | 452.8% | 338.2% | 463.6% | 305.7% | 459.1% | 366.6% | 301.5% | 493.9% | 448.4% | 415.4% | 442.6% | 679.7% | 361.2% | 149.2% | 259.1% | 327.9% | 301.5% | 404.6% | 440.7% | 506.1% | 377.5% | 177.3% | 63.3% | 34.1% | 1,345.8% | 42.6% | 265.5% | |
| -13.0% | -14.0% | -4.0% | -588.7% | -352.8% | -238.2% | -363.6% | -205.7% | -359.1% | -266.6% | -201.5% | -393.9% | -348.4% | -315.4% | -342.6% | -579.7% | -261.2% | -49.2% | -159.1% | -227.9% | -201.5% | -304.6% | -340.7% | -406.1% | -277.5% | -77.3% | 36.7% | 65.9% | -1,245.8% | 57.4% | -165.5% | |
| 113.0% | 114.0% | 104.0% | 688.7% | 452.8% | 338.2% | 463.6% | 305.7% | 459.1% | 366.6% | 301.5% | 493.9% | 448.4% | 415.4% | 442.6% | 679.7% | 361.2% | 149.2% | 259.1% | 327.9% | 301.5% | 404.6% | 440.7% | 506.1% | 377.5% | 177.3% | 1,091.0% | 595.9% | 1,345.8% | 969.3% | 921.5% | |
| 18.1% | 19.8% | 20.6% | 139.7% | 85.5% | 78.2% | 106.2% | 93.5% | 130.3% | 105.9% | 81.4% | 119.2% | 95.9% | 84.4% | 90.3% | 138.1% | 77.4% | 38.1% | 57.5% | 71.1% | 71.1% | 96.8% | 93.1% | 80.7% | 63.2% | 32.4% | 166.7% | 100.5% | 233.7% | 172.4% | 155.1% | |
| 18.1% | 19.8% | 20.6% | 139.7% | 85.5% | 78.2% | 106.2% | 93.5% | 130.3% | 105.9% | 81.4% | 119.2% | 95.9% | 84.4% | 90.3% | 138.1% | 77.4% | 38.1% | 57.5% | 71.1% | 71.1% | 96.8% | 93.1% | 80.7% | 63.2% | 32.4% | 1,194.3% | 677.9% | 233.7% | 1,099.2% | 816.9% | |
| -31.1% | -33.8% | -24.7% | -728.5% | -438.3% | -316.4% | -469.8% | -299.1% | -489.4% | -372.5% | -282.8% | -513.2% | -444.3% | -399.9% | -432.9% | -717.8% | -338.6% | -87.3% | -216.7% | -299.1% | -272.6% | -401.4% | -433.8% | -486.7% | -340.7% | -109.7% | -1,157.7% | -612.0% | -1,479.4% | -1,041.7% | -982.4% | |
| – | – | 1.8% | 13.7% | 6.0% | 5.3% | 16.5% | 2.0% | 6.3% | 2.4% | 0.4% | 4.0% | 2.2% | 2.7% | 9.4% | 73.9% | 42.6% | 8.1% | – | 52.0% | – | – | – | – | – | – | – | – | – | – | – | |
| -29.0% | -32.4% | -22.8% | -714.8% | -432.3% | -311.0% | -453.3% | -297.1% | -483.0% | -370.1% | -282.5% | -509.2% | -442.1% | -397.1% | -423.6% | -688.7% | -321.1% | -79.1% | -200.3% | -276.8% | -249.8% | -367.6% | -388.3% | -440.7% | -305.4% | -96.9% | -1,094.8% | -576.1% | -1,394.3% | -993.1% | -929.2% | |
| 0.1% | 0.1% | 0.1% | 11.3% | 0.4% | -492.3% | -16.5% | 0.6% | 1.4% | 2.0% | -1.2% | 0.6% | -2.2% | -2.7% | -9.4% | -73.9% | -42.6% | -8.1% | 18.5% | 52.0% | 0.5% | 0.7% | 0.7% | 0.1% | – | 1.7% | – | – | – | -3.0% | – | |
| -29.1% | -32.5% | -22.9% | -726.0% | -432.6% | 181.3% | -453.3% | -297.7% | -484.4% | -372.0% | -281.3% | -509.8% | -442.1% | -397.1% | -423.6% | -688.7% | -321.1% | -79.1% | -200.3% | -276.8% | -250.3% | -368.4% | -388.9% | -440.7% | -305.4% | -98.7% | -1,094.8% | -576.1% | -1,394.3% | -990.1% | -928.4% | |
| -24.1% | -27.4% | -19.4% | -699.0% | -421.2% | -304.5% | -456.4% | -289.5% | -476.5% | -363.4% | -275.2% | -498.9% | -431.8% | -385.9% | -410.1% | -682.6% | -307.3% | -73.0% | -189.7% | -273.3% | -237.5% | -348.4% | -369.2% | -431.3% | -292.6% | -91.8% | -1,031.4% | -542.0% | -1,333.9% | -950.5% | -882.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.